Potential impact of nonavalent HPV vaccine in the prevention of high‐grade cervical lesions and cervical cancer in Portugal

Objective To estimate the potential impact of the nonavalent HPV vaccine for high‐grade cervical lesions and invasive cervical cancer ( ICC ) in Portugal. Methods The present secondary analysis used data collected in the CLEOPATRE II study on the prevalence of HPV 6/11/16/18/31/33/45/52/58 among female patients aged 20–88 years. The prevalence of HPV types in patients with cervical intraepithelial neoplasia ( CIN ) grades 2/3 and ICC was examined. Results Data were included from 582 patients. There were 177, 341, and 64 patients with CIN 2, CIN 3, and ICC , respectively, and 169 (95.5%), 339 (99.4%), and 62 (96.9) of them had HPV infections. Of patients with HPV infections, HPV 16, 18, 31, 33, 45, 52, and 58 infections were identified in 150 (88.8%), 329 (97.1%), and 60 (96.8%) patients with CIN 2, CIN 3, and ICC , respectively. HPV genotypes 6, 11, 16, 18, 31, 33, 45, 52, and 58 were identified in 540 (94.7%) of the patients with HPV infections. Conclusion The addition of the five HPV genotypes included in the nonavalent HPV vaccine ( HPV 31/33/45/52/58) could result in the new HPV vaccine preventing 94.7% of CIN 2/3 and ICC occurrences.